Related Experiment Video
Updated: Aug 15, 2026

Assays for Validating Histone Acetyltransferase Inhibitors
Published on: August 6, 2020
Regulation of Kruppel-like factor 6 tumor suppressor activity by acetylation
Dan Li1, Steven Yea, Georgia Dolios
1Department of Human Genetics, Mount Sinai School of Medicine, New York, NY 10029-6574, USA.
Abstract:
Krüppel-like factor 6 (KLF6) is a zinc finger transcription factor and tumor suppressor that is inactivated in a number of human cancers by mutation, allelic loss, and/or promoter methylation. A key mechanism of growth inhibition by wild-type KLF6 is through p53-independent up-regulation of p21(WAF1/cip1) (CDKN1A), which is abrogated in several tumor-derived mutants. Here we show by chromatin immunoprecipitation that transactivation of p21(WAF1/cip1) by KLF6 occurs through its direct recruitment to the p21(WAF1/cip1) promoter and requires acetylation by histone acetyltransferase activity of either cyclic AMP-responsive element binding protein-binding protein or p300/CBP-associated factor. Direct lysine acetylation of KLF6 peptides can be shown by mass spectrometry. A single lysine-to-arginine point mutation (K209R) derived from prostate cancer reduces acetylation of KLF6 and abrogates its capacity to up-regulate endogenous p21(WAF1/cip1) and reduce cell proliferation. These data indicate that acetylation may regulate KLF6 function, and its loss in some tumor-derived mutants could contribute to its failure to suppress growth in prostate cancer.
Insights
Krüppel-like factor 6 (KLF6), a tumor suppressor, regulates cell growth by increasing p21 expression. Acetylation of KLF6 is crucial for this function, and its loss in cancer mutants impairs tumor suppression.
Area of Science:
- Molecular Biology
- Cancer Research
- Epigenetics
Background:
- Krüppel-like factor 6 (KLF6) is a tumor suppressor gene frequently inactivated in human cancers.
- Wild-type KLF6 inhibits tumor growth partly by up-regulating p21(WAF1/cip1) (CDKN1A) in a p53-independent manner.
- This growth-inhibitory function is often lost in tumor-derived KLF6 mutants.
Purpose of the Study:
- To investigate the role of KLF6 acetylation in its transcriptional activity and tumor suppressive function.
- To determine if KLF6 is directly recruited to the p21(WAF1/cip1) promoter and if its acetylation is required for transactivation.
Main Methods:
- Chromatin immunoprecipitation (ChIP) to assess KLF6 recruitment to the p21(WAF1/cip1) promoter.
- Mass spectrometry to detect direct lysine acetylation of KLF6 peptides.
- Site-directed mutagenesis (K209R) to evaluate the impact of acetylation on KLF6 function.
Main Results:
- KLF6 is directly recruited to the p21(WAF1/cip1) promoter.
- KLF6 acetylation by histone acetyltransferases (e.g., p300/CBP) is essential for p21(WAF1/cip1) up-regulation.
- A prostate cancer-derived KLF6 mutant (K209R) shows reduced acetylation, impaired p21(WAF1/cip1) induction, and diminished cell proliferation inhibition.
Conclusions:
- Acetylation is a critical post-translational modification regulating KLF6 transcriptional activity.
- Loss of KLF6 acetylation in cancer mutants contributes to its failure to suppress tumor growth, particularly in prostate cancer.
Related Concept Videos
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein.
Abnormal Proliferation
Spreading of Chromatin Modifications
Writers
The writer is an enzyme that can...
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
Master Transcription Regulators
